What's breaking now, across thousands of outlets.
After winning FDA approval at the end of last year, two nonprofits are now launching their rare immune disease gene therapy Waskyra with a list price of $3.25 million, they told Endpoints News. The nonprofits — ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
Depression may be an overlooked factor in cancer outcomes, according to a large SEER-Medicare analysis of more than 265,000 adults with six common cancers.
Kenya’s Pharmacy and Poisons Board (PPB) has issued an urgent public alert after detecting falsified Lucentis (Ranibizumab) 0.3 mg eye injections circulating in the Kenyan market, warning that the…
These 20 habits for healthy aging draw on Harvard Health guidance and new longevity research covering movement, sleep, diet and connection
In a Facebook post, Leader of the Opposition highlights the voice message of the Director of Health Services, circulated in a group of district medical officers, which urged hospital superintendents…
Data from an early trial showed the company’s “gamma delta” cell therapy surpassed benchmarks set by personalized CAR-T treatments tested in lupus.
